IN2012DN01966A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01966A IN2012DN01966A IN1966DEN2012A IN2012DN01966A IN 2012DN01966 A IN2012DN01966 A IN 2012DN01966A IN 1966DEN2012 A IN1966DEN2012 A IN 1966DEN2012A IN 2012DN01966 A IN2012DN01966 A IN 2012DN01966A
- Authority
- IN
- India
- Prior art keywords
- alkyl group
- hydrogen atom
- following formula
- group
- substituent
- Prior art date
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: wherein R is a hydrogen atom or a C1-10 alkyl group; R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group or a substituent having the structure represented by the following formula la or lb: where R3 is a C1-6 alkyl group; R4 is a C1-6 alkyl group, a C3-8 cycloalkyl group, or a benzyl group; and R2 is a hydrogen atom or a substituent having the structure represented by the following formula Ic or Id:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009215093 | 2009-09-17 | ||
| JP2010103546 | 2010-04-28 | ||
| PCT/JP2010/066637 WO2011034215A1 (en) | 2009-09-17 | 2010-09-17 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01966A true IN2012DN01966A (en) | 2015-08-21 |
Family
ID=43758807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1966DEN2012 IN2012DN01966A (en) | 2009-09-17 | 2010-09-17 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120172598A1 (en) |
| EP (1) | EP2477989A4 (en) |
| JP (1) | JP2013505202A (en) |
| AR (1) | AR078424A1 (en) |
| AU (1) | AU2010296312A1 (en) |
| CA (1) | CA2773125A1 (en) |
| IN (1) | IN2012DN01966A (en) |
| NZ (1) | NZ598478A (en) |
| SG (1) | SG179176A1 (en) |
| TW (1) | TW201121964A (en) |
| WO (1) | WO2011034215A1 (en) |
| ZA (1) | ZA201201528B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| BR0307033A (en) * | 2002-01-22 | 2004-12-07 | Pfizer | 3- (imidazolyl) -2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| EP2361910A4 (en) * | 2008-10-29 | 2012-08-01 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
-
2010
- 2010-09-16 TW TW099131555A patent/TW201121964A/en unknown
- 2010-09-16 AR ARP100103378A patent/AR078424A1/en not_active Application Discontinuation
- 2010-09-17 CA CA2773125A patent/CA2773125A1/en not_active Abandoned
- 2010-09-17 AU AU2010296312A patent/AU2010296312A1/en not_active Abandoned
- 2010-09-17 WO PCT/JP2010/066637 patent/WO2011034215A1/en active Application Filing
- 2010-09-17 US US13/496,625 patent/US20120172598A1/en not_active Abandoned
- 2010-09-17 EP EP10817326A patent/EP2477989A4/en not_active Withdrawn
- 2010-09-17 IN IN1966DEN2012 patent/IN2012DN01966A/en unknown
- 2010-09-17 JP JP2012506827A patent/JP2013505202A/en not_active Withdrawn
- 2010-09-17 NZ NZ598478A patent/NZ598478A/en not_active IP Right Cessation
- 2010-09-17 SG SG2012018644A patent/SG179176A1/en unknown
-
2012
- 2012-02-29 ZA ZA2012/01528A patent/ZA201201528B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG179176A1 (en) | 2012-04-27 |
| EP2477989A1 (en) | 2012-07-25 |
| NZ598478A (en) | 2013-01-25 |
| WO2011034215A1 (en) | 2011-03-24 |
| AU2010296312A1 (en) | 2012-03-29 |
| US20120172598A1 (en) | 2012-07-05 |
| TW201121964A (en) | 2011-07-01 |
| CA2773125A1 (en) | 2011-03-24 |
| AR078424A1 (en) | 2011-11-09 |
| JP2013505202A (en) | 2013-02-14 |
| EP2477989A4 (en) | 2013-03-13 |
| ZA201201528B (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009354A (en) | Pyridazinone compound and use thereof. | |
| TNSN08407A1 (en) | Organic compounds | |
| ES2531056T3 (en) | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | |
| NO20084456L (en) | Organic compounds | |
| NO20083717L (en) | Pyrrolotriazine-aniline prodrugs useful as kinase inhibitors | |
| TN2009000024A1 (en) | Prodrug of cinnamide compound | |
| JO2967B1 (en) | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | |
| NZ592497A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| EA201290397A1 (en) | 1,3,4-OXADIAZOL-2-CARBOXAMIDE COMPOUND | |
| MX2010013768A (en) | Nucleoside cyclicphosphates. | |
| EP1845081A4 (en) | Amide compound | |
| CR20120053A (en) | JAK DE PIRAZOLOPIRIMIDINA INHIBITING COMPOUNDS AND METHODS | |
| MY150507A (en) | Polycyclic compound | |
| ES2723277T3 (en) | A solid form of (S) -3- (4 - ((4-morpholinomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2,6-dione hydrochloride | |
| PH12015500209A1 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
| UA105185C2 (en) | Pyrrols | |
| MX2014000452A (en) | Azabenzimidazole derivative having ampk-activating activity. | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| MY159870A (en) | Piperazine compound capable of inhibiting prostaglandin d synthase | |
| MX2012002528A (en) | Therapeutic agent for mood disorders. | |
| UA102310C2 (en) | Heterocyclic sufonamides, use thereof and pharmaceuticsl compositions | |
| WO2008136378A1 (en) | Novel sulfonamide derivative and salt thereof | |
| MY161992A (en) | Novel tetrahydroisoquinoline derivative | |
| MX343077B (en) | Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these. | |
| UA111950C2 (en) | HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISORDERS CAUSED BY REDUCED NERROTRANSMISSION OF SEROTONIN, NOREPINEPHIN OR DOPIN |